Breaking News

Breaking News: JNC 8 Guidelines Released

December 19, 2013
Breaking News: JNC 8 Guidelines Released

By Monica Gupta, MD

On December 18, 2013, the long awaited JNC 8 guidelines were published. Two major deviations from JNC 7 are: 1) more relaxed blood pressure goals and cutoffs for initiation of treatment, and 2) recommendations for first line therapy.

Simplified, JNC 8’s major recommendations are as follows:

In those 60 years or older, blood pressure lowering agents should be initiated to achieve a goal SBP < 150 mmHg and a goal DBP < 90 mmHg. In those 60 years or younger,

Read more »

Clinical Correlations Awarded Platinum eHealthcare Leadership Award

December 18, 2013
Clinical Correlations Awarded Platinum eHealthcare Leadership Award

We are very pleased to announce that Clinical Correlations has been awarded a 2013 Platinum eHealthcare Leadership Award. Now in it’s 14th year, this awards program, is the largest web-oriented awards program that is focused exclusively on healthcare. The program attracts over 1100 entrants. Winners were recently recognized during a special presentation at the Seventeenth Annual Healthcare Internet Conference held in New Orleans. Although we have won prior Gold awards, this is the first time we have been recognized at the platinum level in the Best…

Read more »

BREAKING NEWS: New ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

November 13, 2013
BREAKING NEWS: New ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

By Sherif Shoucri, MD

Yesterday, the American College of Cardiology and American Heart Association released new groundbreaking guidelines on the treatment of blood cholesterol. These recommendations, which officially drop LDL target levels for patients on statin therapy, will fundamentally alter the way most primary care physicians and cardiologists treat hyperlipidemia. After reviewing the available data on statins, the authors concluded that there was no evidence to support an LDL target of either 70 or 100. Rather, patients should be placed on either moderate-intensity (lowers…

Read more »

Breaking News: The Downfall of the PSA

May 23, 2012
Breaking News: The Downfall of the PSA

The United States Preventive Services Task Force stands their ground in this week’s Annals of Internal Medicine and recommends against the routine use of the PSA as a screening tool for prostate cancer. This Class D recommendation is grounded in data that suggests a “very small” mortality benefit at the risk of significant over-diagnosis and unnecessary treatment. The PSA should still be used to follow response to treatment in those already diagnosed with prostate cancer. This recommendation has already set off a media frenzy and…

Read more »

Clinical Correlations Wins 2012 Gold Award from the American Society of Healthcare Publication Editors

May 21, 2012
Clinical Correlations Wins 2012 Gold Award from the American Society of Healthcare Publication Editors

With Primecuts on a brief hiatus this week, I thought it would be a great opportunity to do a bit of bragging…

I am very pleased to announce that Clinical Correlations has received a 2012 Gold Award from the American Society of Healthcare Publication Editors (ASHPE).

From the Awards Announcement:

“The American Society of Healthcare Publication Editors recognizes editorial excellence and achievement in the field of healthcare publishing. The annual awards competition provides an opportunity for editors to measure their efforts and publications against the…

Read more »

Breaking News: FDA issues new dosing limitations for Simvastatin

June 10, 2011
Breaking News: FDA issues new dosing limitations for Simvastatin

By Saleem Ali, MD

The FDA has issued new warnings regarding the use of high dose Simvastatin. The FDA is now recommending that the 80mg dose only be used in patients who have been taking that dosage for at least 12 months with no signs of toxicity.  Patients who are currently on simvastatin and require more than 40 mg. should be considered for alternative lipid lowering therapy. The FDA is issuing this warning because recent data has shown that the 80 mg. dose has a…

Read more »

Spring Cleaning-Introducing Clinical Correlations 3.0

May 24, 2011
Spring Cleaning-Introducing Clinical Correlations 3.0


Welcome to Clinical Correlations 3.0.  In case you forgot, we already did 2.0 a few years ago, so it seemed the time was ripe to evolve once again. We’ve redesigned the site from the ground up to give you a clear, crisp website that hopefully catches your eye before it catches your brain.  Over the next several months we’re hoping to refresh not only the interface, but the content as well; more frequent posts, faster hitting pieces that teach you something new each and every day. …

Read more »

Happy New Year…and Happy 4th Birthday to Us!

January 1, 2011
Happy New Year…and Happy 4th Birthday to Us!

Four years and still going strong.  It’s hard to believe.  If you told me when we first launched Clinical Correlations that we would have posted over 700 articles tackling a potpourri of internal medicine, average 1000 hits/day with readers from all over the world, I would have laughed at the ridiculousness of the thought.  But here we are four years later and I am so proud of all we have accomplished.  I’m frequently asked  about our motivation-and to be honest, I never give the…

Read more »

Off Label

November 19, 2010
Off Label

By Alexander Volodarskiy, MD

Faculty Peer Reviewed

In a press conference on April 27, 2010, Attorney-General Eric Holder announced that AstraZeneca had agreed to pay a $520 million fine to settle an investigation into the marketing practices of its blockbuster drug, quetiapine (Seroquel) . According to federal investigators, quetiapine, originally approved by the FDA in 1997 for the treatment of schizophrenia and bipolar mania, was promoted by AstraZeneca for use in unapproved (and far commoner) conditions, such as anxiety…

Read more »

Breaking News: Lung Cancer Screening Shows Mortality Benefit

November 5, 2010
Breaking News: Lung Cancer Screening Shows Mortality Benefit

By David Hormozdi, MD

The weather outside may be cooling off but the debate surrounding lung cancer screening is heating up once again as preliminary results released from The National Lung Screening Trial (NLST) showed 20% fewer lung cancer deaths in individuals that underwent screening with low-dose helical CT scans compared to chest X-ray. This is the first study to show a mortality benefit from lung cancer screening and could impact millions of people considered high-risk for lung cancer.  The study’s…

Read more »

Clinical Correlations Wins 2010 Gold Award as Best Blog from the American Society of Healthcare Publication Editors

May 13, 2010
Clinical Correlations Wins 2010 Gold Award as Best Blog from the American Society of Healthcare Publication Editors

I am pleased to announce that Clinical Correlations has received the 2010 Gold Award as best blog from the American Society of Healthcare Publication Editors.

From the award announcement:

The American Society of Healthcare Publication Editors (ASHPE) recognizes editorial excellence and achievement in the field of healthcare publishing. The annual awards competition provides an opportunity for editors to measure their efforts and publications against the very best the healthcare sector has to offer. You can be proud that your…

Read more »

Breaking News: The Crestor Controversy

April 1, 2010
Breaking News: The Crestor Controversy

Devyani Kothari, MD

Patients are already talking about a New York Times front page article highlighting the risks associated with statin use as a preventive measure for cardiovascular events in relatively “healthy” people. The piece examines the newest FDA indications for the use of Crestor along with the controversies surrounding the drug.

Last month, the FDA approved Rosuvastatin Calcium, marketed as Crestor by AstraZeneca for use in a new patient population , based on the JUPITER trial. Crestor now…

Read more »